Described are peptides and polypeptides derived from the MUC-1 polypeptide which are able to activate Cytotoxic T Lymphocyte (CTL) response, analogues of such peptides and polypeptides nucleotide sequences encoding such peptides and polypeptides and therapeutic uses thereof. Moreover, indications for selecting appropriate minimal antigenic MUC-1 polypeptides with reference to the HLA-type of the patient to be treated or tested are described.
申请公布号
WO0118035(A9)
申请公布日期
2002.09.06
申请号
WO2000EP08761
申请日期
2000.09.07
申请人
TRANSGENE S.A.;IMPERIAL CANCER RESEARCH TECHNOLOGY, LTD.